GlassScriptPhysician profile
Jason Tyler Given
NPI 1275739922
$3,013.90
in general payments reported to CMS, 2019-2025
33 companies · $809 in 2025
The $809 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.32 · 2021: $326 · 2022: $626 · 2023: $672 · 2024: $565 · 2025: $809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,046.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $862.39 | 2021-2025 | |
| Abbott Laboratories | $275.15 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $246.94 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $193.00 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $192.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $162.83 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $147.23 | 2024-2025 | Caplyta |
| Pfizer INC. | $112.07 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.50 | 2021-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $86.20 | 2021-2025 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $68.66 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $58.42 | 2021-2022 | |
| Gilead Sciences, INC. | $51.37 | 2021-2022 | |
| Redhill Biopharma INC. | $45.96 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.85 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $40.15 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lundbeck LLC | $33.98 | 2025 | Rexulti |
| Integra Lifesciences Corporation | $28.51 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Exact Sciences Corporation | $27.90 | 2023 | Cologuard Collection Kit |
| Dexcom, INC. | $27.48 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $20.68 | 2022 | |
| Amarin Pharma, INC. | $20.52 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $19.36 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.72 | 2023 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $15.99 | 2024 | Arexvy, Trelegy Ellipta |
| Horizon Therapeutics Plc | $14.86 | 2023 | Krystexxa |
| Phathom Pharmaceuticals, INC. | $14.42 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $14.42 | 2023 | Gvoke Hypopen |
| Photonicare INC | $13.94 | 2025 | Otosight Middle Ear Scope |
| Azurity Pharmaceuticals, INC. | $13.61 | 2025 | Azmiro |
| Idorsia Pharmaceuticals US INC | $12.95 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $12.62 | 2021 | |
| Acerus Pharmaceuticals Corporation | $11.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Given listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.